|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
US10287354B2
(en)
|
2013-12-20 |
2019-05-14 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
US11028143B2
(en)
|
2014-01-21 |
2021-06-08 |
Novartis Ag |
Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
JP7585034B2
(ja)
|
2017-10-18 |
2024-11-18 |
ノバルティス アーゲー |
選択的タンパク質分解のための組成物及び方法
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
CN109517073A
(zh)
*
|
2018-11-30 |
2019-03-26 |
北京泽勤生物医药有限公司 |
一种靶向治疗肿瘤的融合肽及其应用
|
|
WO2020122104A1
(ja)
|
2018-12-11 |
2020-06-18 |
国立大学法人京都大学 |
ゲノムｄｎａに欠失を誘導する方法
|
|
WO2020206055A1
(en)
*
|
2019-04-02 |
2020-10-08 |
Yale University |
Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
|
|
EP3962938A4
(en)
|
2019-05-01 |
2023-07-05 |
PACT Pharma, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING CD8 MODIFIED T LYMPHOCYTE CELL THERAPY
|
|
US12344656B2
(en)
|
2019-09-06 |
2025-07-01 |
Crispr Therapeutics Ag |
Genetically engineered T cells having improved persistence in culture
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
AU2020405049A1
(en)
*
|
2019-12-17 |
2022-06-23 |
The General Hospital Corporation |
Engineered immune cells with reduced toxicity and uses thereof
|
|
KR20210103975A
(ko)
*
|
2020-02-14 |
2021-08-24 |
(주)이뮤노텍바이오팜코리아 |
외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도
|
|
WO2021188836A1
(en)
*
|
2020-03-18 |
2021-09-23 |
Barron Annelise E |
Upregulation of cathelicidin gene expression as an adjuvant to other treatments for diseases
|
|
EP4168451A2
(en)
|
2020-06-22 |
2023-04-26 |
NGM Biopharmaceuticals, Inc. |
Lair-1-binding agents and methods of use thereof
|
|
US20230302155A1
(en)
|
2020-08-21 |
2023-09-28 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
CN113980134B
(zh)
|
2020-12-11 |
2022-05-31 |
广州百暨基因科技有限公司 |
抗cll1抗体及其应用
|
|
CN113234169B
(zh)
*
|
2020-12-11 |
2022-11-01 |
广州百暨基因科技有限公司 |
靶向cll1嵌合抗原受体及其应用
|
|
WO2023086882A1
(en)
*
|
2021-11-11 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout
|
|
KR102521500B1
(ko)
*
|
2021-12-02 |
2023-04-14 |
한국화학연구원 |
증진된 효능을 갖는 면역세포
|
|
CN114350665A
(zh)
*
|
2022-01-19 |
2022-04-15 |
上海优替济生生物医药有限公司 |
IFN-γ抑制剂及其用途
|
|
CN114404592A
(zh)
*
|
2022-02-09 |
2022-04-29 |
复旦大学附属中山医院 |
Tet2作为靶标在治疗缺血性血管疾病中的应用
|
|
US20260083844A1
(en)
*
|
2022-09-15 |
2026-03-26 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Downregulating inos to increase car-t killing
|
|
WO2025189025A2
(en)
*
|
2024-03-07 |
2025-09-12 |
Biontech Us Inc. |
Methods and compositions for engineering t cells
|